Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
BACKGROUND
Pamidronate is used extensively for treatment of osteoporotic and high bone turnover conditions. Because it has a long retention time in the human skeleton, concerns have been raised as to safety profile in women of child-bearing age.


METHODS
Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data.


RESULTS
Each pregnancy was uncomplicated, and the four offspring are healthy, with no evidence of biochemical or skeletal abnormality.


CONCLUSIONS
We found no evidence for adverse effects of prepregnancy pamidronate on maternal or fetal health. Until the results of systematic studies are available, caution is recommended regarding pamidronate use in women of child-bearing years.
Department of Endocrinology and Diabetes, Royal Children's Hospital, Flemington Road, Parkville 3052, Victoria, Australia.
Brendan
B
Chan
Margaret
M
Zacharin
D000328:Adult; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005359:Fibrous Dysplasia, Polyostotic / Q000188:drug therapy*; D006801:Humans; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate; D002118:Calcium